Cutaneous adverse drug reactions in the elderly

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 4, 2015, Pages 300-307

  Heng, Yee Kiat ^a   Lim, Yen Loo ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

Author keywords

drug eruption; elderly; polypharmacy; toxic epidermal necrolysis

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE;

ADVERSE OUTCOME; AGED; ALOPECIA; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL EVALUATION; CLINICAL PRACTICE; COMEDO; COMORBIDITY; CUTANEOUS ADVERSE DRUG REACTION; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ECZEMA; EPIDEMIOLOGICAL DATA; HUMAN; HYPERPIGMENTATION; LONG TERM CARE; MANAGED CARE; MOLECULAR THERAPY; MUCOSA INFLAMMATION; NAIL DISEASE; PAPULE; PARONYCHIA; PRIORITY JOURNAL; PROGNOSIS; PROVOCATION TEST; PSORIASIS; PUSTULE; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; XEROSIS; AGING; MORTALITY; NEOPLASMS; PATHOLOGY; STEVENS-JOHNSON SYNDROME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; CALCIUM CHANNEL BLOCKERS; HUMANS; HYDROCHLOROTHIAZIDE; NEOPLASMS; PROGNOSIS; STEVENS-JOHNSON SYNDROME;

EID: 84937809961     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000181     Document Type: Review

References (70)

1. World Health Organization The uses of epidemiology in the study of the elderly. Geneva: WHO; 1984
2. World Population Ageing. Population division, Department of Economic and Social Affairs, United Nations Secretariat. 2013. http://www.un.org/en/development/desa/population/publi-cations/pdf/ageing/WorldPopulation Ageing2013.pdf. [Accessed 2 January 2015]
3. Schäfer I, Hansen H, Schön G, et al. The influence of age, gender and socioeconomic status on multimorbidity patterns in primary care. First results from the multicare cohort study. BMC Health Serv Res 2012; 12: 89
4. Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist 2010; 15: 507-522
5. Jerez-Roig J, Medeiros LF, Silva VA, et al. Prevalence of self-medication and associated factors in an elderly population: a systematic review. Drugs Aging 2014; 31: 883-896
6. Doña I, Barrionuevo E, Blanca-Lopez N, et al. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol 2014; 24: 143-153
7. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf 2012; 11: 83-94
8. Ahmed AM, Pritchard S, Reichenberg J A review of cutaneous drug eruptions. Clin Geriatr Med 2013; 29: 527-545
9. Carneiro SC, Azevedo-e-Silva MC, Ramos-e-Silva M. Drug eruptions in the elderly. Clin Dermatol 2011; 29: 43-48
10. Tuchinda P, Chularojanamontri L, Sukakul T, et al. Cutaneous adverse drug reactions in the elderly: a retrospective analysis in Thailand. Drugs Aging 2014; 31: 815-824
11. Kim JY, Lee J, Ko YJ, et al. Multi-indication carbamazepine and the risk of severe cutaneous adverse drug reactions in Korean elderly patients: a Korean health insurance data-based study. PLoS One 2013; 8: e83849
12. Joly P, Benoit-Corven C, Baricault S, et al. Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study. J Invest Dermatol 2007; 127: 2766-2771
13. Summers EM, Bingham CS, Dahle KW, et al. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. J Am Med Assoc Dermatol 2013; 149: 814-818
14. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011; 71: 684-700
15. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy 2012; 97: 1-17
16. Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 2005; 22: 767-777
17. Fiszenson-Albala F, Auzerie V, Mahe E, et al A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149: 1018-1022
18. Hernández-Salazar A, Rosales SP, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions A prospective study in hospitalized patients. Arch Med Res 2006; 37: 899-902
19. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions A report from the Boston Collaborative Drug Surveillance Program on 15, 438 consecutive inpatients, 1975-1982. J Am Med Assoc 1986; 256: 3358-3363
20. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010; 49: 834-841
21. Zhong H, Zhou Z, Wang H, et al. Prevalence of cutaneous adverse drug reactions in Southwest China: an 11-year retrospective survey on in-patients of a dermatology ward. Dermatitis 2012; 23: 81-85
22. Apaydin R, Bilen N, Dökmeci S, et al. Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospital. J Eur Acad Dermatol Venereol 2000; 14: 518-520
23. Barbaud A, Reichert-Penetrat S, Trechot P, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139: 49-58
24. Chen CJ, Cheng CF, Lin HY, et al A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system. J Clin Pharm Ther 2012; 37: 647-651
25. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28: 443-452
26. Ball P, Mandell L, Patou G, et al A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004; 23: 421-429
27. Chng HH, Leong KP, Cheng YK, et al. Elderly inpatients have drug allergy manifestations and outcome similar to the nonelderly but serious reactions are less common: results of a 9-year prospective study. Allergy 2008; 63 (Suppl 88): 379
28. Yalcin B, Tamer E, Toy GG, et al. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. Int J Dermatol 2006; 45: 672-676
29. Morin C, Joly P, Courville P, et al. Chronic eczematiform eruption in the elderly [in French]. Ann Dermatol Venereol 2002; 129: 19-22
30. Rinnerthaler M, Streubel MK, Bischof J, Richter K. Skin aging, gene expression and calcium. Exp Gerontol 2014. doi: 10.1016/j.exger.2014.09.015
31. Rinnerthaler M, Duschl J, Steinbacher P, et al. Age-related changes in the composition of the cornified envelope in human skin. Exp Dermatol 2013; 22: 329-335
32. Mauro T, Guitard M, Behne M, et al. The ENaC channel is required for normal epidermal differentiation. J Invest Dermatol 2002; 118: 589-594
33. Vena GA, Cassano N, Coco V, De Simone C. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol 2013; 35: 447-450
34. Kerasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 1993; 186: 248-252
35. Cohen AD, Bonneh DY, Reuveni H, et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol 2005; 85: 299-303
36. Wolkenstein P, Revuz J, Roujeau JC, et al. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology 2009; 218: 103-109
37. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386
38. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol 2014; 71: 203; e1-12
39. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59: 524-529
40. Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 2011; 65: 624-635
41. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol 2014; 71: 217; e1-11
42. Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximabrelated skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013; 132: 236-245
43. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009; 77: 257-271
44. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44
45. Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011; 32: 237-245
46. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40
47. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol 2013; 169: 1304-1309
48. Weinand C, Xu W, Perbix W, et al. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. Burns 2013; 39: 1449-1455
49. Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 2014; 71: 941-947
50. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010; 146: 1373-1379
51. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 1071-1080
52. Lee HY, Lie D, Lim KS, et al. Strontiumranelate-induced toxic epidermal necrolysis in a patient with postmenopausal osteoporosis. Osteoporos Int 2009; 20: 161-162
53. Tan KW, Wang YS, Tay YK. Stevens-Johnson syndrome due to strontium ranelate. Ann Acad Med Singapore 2011; 40: 510-511
54. Yang CY, Chen CH, Wang HY, et al. Strontium ranelate related Stevens-Johnson syndrome: a case report. Osteoporos Int 2014; 25: 1813-1816
55. Cacoub P, Descamps V, Meyer O, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. Osteoporos Int 2013; 24: 1751-1757
56. Musette P, Brandi ML, Cacoub P, et al. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010; 21: 723-732
57. Lin YF, Yang CH, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis 2014; 58: 1377-1385
58. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013; 69: 187; e1-16
59. Duong TA, de Prost N, Ingen-Housz-Oro S, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. Br J Dermatol 2015; 172: 400-405
60. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis: improving the support to victims. Drug Saf 2013; 36: 145-146
61. Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol 2008; 22: 1044-1049
62. Yang MS, Kang MG, Jung JW, et al. Clinical features and prognostic factors in severe cutaneous drug reactions. Int Arch Allergy Immunol 2013; 162: 346-354
63. Kim DH, Koh YI.comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Immunol Res 2014; 6: 216-221
64. Chen YC, Chang CY, Cho YT, et al. Long-Term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013; 68: 459-465
65. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257-259
66. Roujeau JC, Bastuji-Garin S. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf 2011; 2: 87-94
67. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-Analysis. Br J Dermatol 2012; 167: 424-432
68. Piaserico S, Larese F, Recchia GP, et al. Allergic contact sensitivity in elderly patients. Aging Clin Exp Res 2004; 16: 221-225
69. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854-863
70. Viola M, Rumi G, Valluzzi RL, et al. Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity. Clin Exp Allergy 2011; 41: 96-103